RGCC Analyses

Description

Circulating Tumor Cells (CTCs) are cells that have detached from the primary tumor and flow into the blood or lymphatic circulation creating a secondary tumor. Despite their rare population, these cells exhibit metastatic attributes and are related to cancer progression.

The R.G.C.C test is a test for patient’s seeking personalised cancer testing where it has the ability to:
-Detect early signs of developing cancer
-Help monitoring existing cancers
-Produce an individual profile of chemotherapeutic drugs and natural substances that can be used to achieve the best treatment outcomes.

Testing Options Available:

Oncocount: Provides information on the presence and the concentration of Circulating Tumor Cells (CTC’s). It enumerates only the progenitor cells that are relevant to potent relapse and recurrence of the disease.

Oncotrace: Provides information about the presence of Circulating Tumor Cells (CTC’s), Their concentration and immunophenotype, which may help identify their origin.

Oncotrail: Provides information about the presence of Circulating Tumor Cells (CTC’s) and their concentration and immunophenotype for specific types of malignancies. This test is a tailor-made test for specific type of malignancies such as breast cancer (Oncotrail R.G.C.C. for Breast), Prostate (Oncotrail for Prostate), Sarcoma etc. This test includes only markers relevant for a specific type of malignancy which make the test a good tool for follow up control.

Onconomics: Provides information about the efficacy of specific drugs on the cancer cells derived from a single patient. The method incorporates two procedures, the epigenetic analysis and the viability assays, to validate the data.

Onconomics Plus: Provides information about the efficacy of specific drugs on the cancer cells derived from a single patient. The method incorporates two procedures (epigenetic analysis and viability assays) to validate the data. The efficacy of natural biological substances or extracts on cancer cells is also referred to. The assessment is based on three methods: the direct cytotoxic effect, stimulation of the immune system and the inhibition of proliferative signals in the cancer cells.

Onconomics Extracts: Provides information about the efficacy of natural biological substances or extracts on cancer cells. The assessment is based on three methods: the direct cytotoxic effect, stimulation of the immune system and the inhibition of proliferative signals in the cancer cells.

Metastat: Markers on CTC’s that point out the potent organ for relapse. From literature, numerous markers are associated with specific tumor organ metastases.
The Metastat test is a collection of specific markers that are detected on specific organs. Cells of the primary tumor that have the ability to metastasize will express specific genes and proteins according to the organ that will metastasize, and that is given by the genetic information.

Immune Frame: Profile of humoral and cellular immunity and cachexia. This test is focusing on the status of the immune system and immunity.

CAMBISeq:  (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.

Sample Reports are available by clicking on the following link:R.G.C.C Sample Report

1- Click on the test type you would like to view. (at the bottom of the page)

2- Click on Sample of the report

3- If you require further information, please contact NutriPATH on 1300 688 522.